Adma Biologics, Inc.
ADMA· Nasdaq
Released Aug 11, 2021, after the close
10-Q filed Aug 11, 2021, 42 days after period end · 0001140361-21-027950
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $17.83M | $7.79M | $6.56M | $4.66M |
| Net Income | -$18.91M | -$20.18M | -$13.21M | -$14.75M |
| EPS Diluted |
Adma Biologics, Inc. · CIK 1368514 · Engraved from SEC EDGAR
| -$0.15 |
| -$0.23 |
| -$0.25 |
| -$0.35 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.